SG/CALL/ELI LILLY & CO/280/0.1/17.01.25 | Delayed Deutsche Boerse AG 03:36:24 01/07/2024 pm IST | ||
| 59.15 EUR | -0.62% |
|
| Current month | +18.85% | ||
| 1 month | +21.35% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 01/24/01 | 59.15 | -0.62% |
| 28/24/28 | 59.52 | +0.63% |
| 27/24/27 | 59.15 | +0.42% |
| 26/24/26 | 58.9 | +0.22% |
| 25/24/25 | 58.77 | +1.70% |
Delayed Quote Deutsche Boerse AG
Last update July 01, 2024 at 03:36 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SV1BZ6 |
| ISIN | DE000SV1BZ67 |
| Date issued | 21/02/2023 |
| Strike | 280 $ |
| Maturity | 17/01/2025 (201 Days) |
| Parity | 10 : 1 |
| Emission price | 8.79 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 59.91 € |
|---|---|
| Lowest since issue | 7.36 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
- Stock Market
- Warrants
- Warrant
